Abstract
When considering the treatment of infantile hemangiomas, several questions must be answered. Whether or not to treat, when to treat, and how to treat. During the past decade, the paradigm for the treatment of hemangiomas has changed. Propranolol has become the first line of therapy. However, there are instances where surgery and or laser treatment is indicated. Lesions that fail to respond or inadequately respond to propranolol, or where propranolol is contraindicated, should be considered. We have selected various anatomical sites to demonstrate the various problems and surgical techniques.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
The location of a hemangioma is not random. Both focal and segmental hemangiomas are found at sites of predilection. Their anatomical location and extent are thus predictable. When confronted with a patient with a hemangioma, the following decisions should be addressed:
-
Should we treat?
-
How should we treat?
-
When should we treat?
The decision should we treat is based on a number of simple variables:
-
1.
Lesions that are clearly exposed warrant treatment (at least 60 % of hemangiomas are central facial lesions).
-
2.
Lesions that are unlikely to involute completely and where treatment will result in a better outcome (50 % of lesions do not involute completely; after the age of 4 years, further involution in any given hemangioma is unlikely).
-
3.
Complications such as ulceration, functional impairment, cardiac failure, and disfigurement.
-
4.
Airway hemangiomas and periocular/orbital hemangiomas.
The decision “how to treat” should be made by a multidisciplinary team. The tendency to use one modality for all lesions should be avoided. The following are important considerations:
-
1.
The type of lesion (focal or segmental)
-
2.
The depth of the lesion
-
3.
The stage of the lesion (proliferating, quiescent, or involuting)
In general, propranolol has replaced corticosteroids as a first line of therapy. All early lesions should be given a trial of propranolol (or timolol if superficial) unless there is a contraindication or some other objection to its use. It should be kept in mind that propranolol does cross the blood-brain barrier and that short-term memory loss is a known side effect in the elderly. For this reason, nadolol, which does not cross the blood-brain barrier and appears to be as effective, is advocated by some. Topical propranolol in one or other form has also become popular for very superficial lesions, and unfortunately, some have used it for deeper lesions. Its efficacy for deeper lesions is in doubt, and the degree of absorption has not yet been determined. One should therefore be cautious when dosing a patient.
A very high percentage of patients respond to propranolol, but it appears that focal lesions do not respond as well. If treated very early, a lesion may shrink and “disappear” or simply stop growing. At present, the proportion and the type of lesion that falls into each of these groups have not yet been determined. Our euphoria with this drug is still prevalent. Realistically, the response to systemic propranolol may be one of the following:
-
1.
The response may be excellent (almost complete or complete shrinkage of the lesion).
-
2.
The lesion may only partially respond (50 % or less). This is more often seen with focal lesions.
-
3.
The lesion may fail to respond. This is seen with some fully grown lesions.
In a small series, 50 % of patients treated with propranolol needed treatment with some other modality (laser or surgery) in order to achieve a satisfactory response. Our belief is that early treatment with propranolol is most beneficial. Lesions will either respond and shrink or simply stop growing. If the lesion being treated was small at the time of commencement, then either of these responses is acceptable. However, when faced with a large lesion, a failure to progress without appreciable shrinkage is not acceptable. In these cases, surgery should be considered. In addition to this, residual cutaneous involvement can and should be treated with a laser.
We therefore only surgically intervene when the lesion warrants treatment, has failed to respond, or inadequately responds to propranolol; in some focal ulcerated hemangiomas in whom surgery will ultimately be needed; and in lesions that are obstructing the airway or visual axis where resolution is urgent. Our surgical approach is determined by the depth of the lesion and its anatomical location. The following examples demonstrate our approach.
Paranasal Hemangiomas
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Italia
About this chapter
Cite this chapter
Waner, M., O, T. (2015). Treatment of Infantile Hemangiomas of the Head and Neck. In: Mattassi, R., Loose, D., Vaghi, M. (eds) Hemangiomas and Vascular Malformations. Springer, Milano. https://doi.org/10.1007/978-88-470-5673-2_16
Download citation
DOI: https://doi.org/10.1007/978-88-470-5673-2_16
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5672-5
Online ISBN: 978-88-470-5673-2
eBook Packages: MedicineMedicine (R0)